Arno Therapeutics Inc (ARNI) Financial Statements (2024 and earlier)

Company Profile

Business Address 200 ROUTE 31 NORTH
FLEMINGTON, NJ 08822
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments937,3552,683,94066,988123,2722,368,1144,934,530
Cash and cash equivalents937,3552,683,94066,988123,2722,368,1144,934,530
Other undisclosed current assets131,451208,644260,694251,170170,338170,523
Total current assets:1,068,8062,892,584327,682374,4422,538,4525,105,053
Noncurrent Assets
Property, plant and equipment19,54221,32223,10324,90826,71428,500
Deposits noncurrent assets10,45510,45510,45510,45510,45510,455
Total noncurrent assets:29,99731,77733,55835,36337,16938,955
TOTAL ASSETS:1,098,8032,924,361361,240409,8052,575,6215,144,008
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities709,401787,8811,010,2151,175,2941,089,013571,538
Accounts payable709,401787,8811,010,2151,175,2941,089,013571,538
Debt4,1493,9983,8533,7133,5773,447
Deferred revenue and credits2,0842,0841,9101,389868347
Other undisclosed current liabilities1,068,852502,0083,214,599983,4601,291,0991,343,978
Total current liabilities:1,784,4861,295,9714,230,5772,163,8562,384,5571,919,310
Noncurrent Liabilities
Long-term debt and lease obligation1,9193,0144,0705,0876,0687,013
Capital lease obligations1,9193,0144,0705,0876,0687,013
Liabilities, other than long-term debt4,530,9115,648,5824,750,6873,485,4375,684,5946,229,359
Derivative instruments and hedges, liabilities4,530,9115,648,5824,750,6873,485,4375,684,5946,229,359
Total noncurrent liabilities:4,532,8305,651,5964,754,7573,490,5245,690,6626,236,372
Total liabilities:6,317,3166,947,5678,985,3345,654,3808,075,2198,155,682
Equity
Equity, attributable to parent, including:(5,218,513)(4,023,206)(8,624,094)(5,244,575)(5,499,598)(3,011,674)
Common stock7,5847,5845,4695,4695,4695,469
Common stock, value, subscriptions      
Additional paid in capital93,920,29192,973,11084,665,39084,049,91983,115,58982,158,638
Accumulated deficit(99,146,388)(97,003,900)(93,294,953)(89,299,963)(88,620,656) 
Other undisclosed equity, attributable to parent      (85,175,781)
Total equity:(5,218,513)(4,023,206)(8,624,094)(5,244,575)(5,499,598)(3,011,674)
TOTAL LIABILITIES AND EQUITY:1,098,8032,924,361361,240409,8052,575,6215,144,008

Income Statement (P&L) (USD)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Operating expenses(3,310,534)(2,825,286)(2,695,538)(2,874,789)(3,979,000)(3,862,484)
Operating loss:(3,310,534)(2,825,286)(2,695,538)(2,874,789)(3,979,000)(3,862,484)
Nonoperating income (expense)1,168,046(883,661)(1,299,452)2,195,482534,125473,693
Other nonoperating income (expense)1,167,349(871,182)(1,272,221)2,195,301531,932469,581
Interest and debt expense(250)(14,518)(27,264)(349)(380)(410)
Loss from continuing operations:(2,142,738)(3,723,465)(4,022,254)(679,656)(3,445,255)(3,389,201)
Loss before gain (loss) on sale of properties:(2,142,738)(3,723,465)(4,022,254)(679,656)(3,445,255)(3,389,201)
Net loss:(2,142,738)(3,723,465)(4,022,254)(679,656)(3,445,255)(3,389,201)
Other undisclosed net income attributable to parent25014,51827,264349380410
Net loss available to common stockholders, diluted:(2,142,488)(3,708,947)(3,994,990)(679,307)(3,444,875)(3,388,791)

Comprehensive Income (USD)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Net loss:(2,142,738)(3,723,465)(4,022,254)(679,656)(3,445,255)(3,389,201)
Comprehensive loss, net of tax, attributable to parent:(2,142,738)(3,723,465)(4,022,254)(679,656)(3,445,255)(3,389,201)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: